One-Time gene therapy aims to free patients from lifelong blood transfusions

NCT ID NCT06308159

Recruiting now Disease control Sponsor: Lantu Biopharma Source: ClinicalTrials.gov ↗

Summary

This trial is testing a one-time gene therapy for people with severe beta-thalassemia who depend on regular blood transfusions. Doctors will collect a patient's own blood stem cells, use a modified virus to insert a healthy hemoglobin gene into them, and then return the cells to the patient. The goal is to see if this treatment is safe and can help the body produce enough healthy red blood cells to reduce or eliminate the need for future transfusions.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
RECRUITING

Kunming, Yunnan, 650100, China

Contact Email: •••••@•••••
Kunming Hope of Health Hospital
RECRUITING

Kunming, Yunnan, 650200, China

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

BETA-THALASSEMIA